Sales Support:
sales@worldwidemarketreports.com
U.S. :+1 415 871 0703
U.K. :+44-203-289-4040
AUS. : +61-2-4786-0457
INDIA :+91-848-285-0837
Menu Icon Close Icon

Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030)

Executive Summary

Azoth Analytics has released a research report titled "Global Neuroendocrine Tumors (NETs) Market (2024 Edition)" which provides a complete analysis of the Global Neuroendocrine Tumors (NETs) industry in terms of market segmentation by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), by Route of Administration (Oral, Parenteral), by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others), by End User (Hospitals, Specialty Clinics, Radiation Centers) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea). The Global Neuroendocrine Tumors (NETs) market showcased growth at a CAGR of 8.98% during 2020-2023. The market was valued at USD 3.57 Billion in 2023 which is expected to reach USD 6.94 Billion in 2030. The market for Neuroendocrine Tumors (NETs) has seen significant growth due to the increasing incidence and prevalence of NETs, rising healthcare expenditure, a growing geriatric population, improvements in healthcare infrastructure, and heightened awareness campaigns and patient advocacy efforts.

Over recent years, there has been a notable rise in the incidence and prevalence of NETs globally. Several factors contribute to this trend, including improved diagnostic techniques leading to better detection rates, heightened awareness among healthcare professionals, and an aging population. As more cases are diagnosed, the demand for diagnostic tests, treatment options, and supportive care services for NET patients continues to grow.

Furthermore, the emergence of targeted therapies and novel treatment modalities has transformed the management of NETs. Somatostatin analogs, such as octreotide and lanreotide, control hormonal symptoms and inhibit tumor growth in certain subtypes of NETs. PRRT delivers targeted radiation to tumor cells expressing somatostatin receptors, offering a promising therapeutic option for patients with advanced disease. Furthermore, ongoing research into immunotherapies, combination therapies, and gene-based approaches holds potential for further expanding the treatment armamentarium for NETs, driving market growth.

Advancement in precision medicine and molecular diagnostics enable personalized treatment strategies tailored to the molecular characteristics of individual tumors. Biomarker-driven approaches identify patients who are most likely to benefit from SSA therapy based on specific tumor markers, somatostatin receptor expression patterns, and genetic alterations. This allows for more targeted and effective treatment selection, optimizing therapeutic outcomes while minimizing unnecessary exposure to medications.

Also, advancement in nanotechnology enable the development of microsphere and nanoparticle formulations for parenteral administration of NETs therapies. These formulations encapsulate the drug within biodegradable polymer matrices or lipid-based nanoparticles, allowing for controlled release and targeted delivery to tumor tissues. Microsphere and nanoparticle formulations offer advantages such as improved drug stability, enhanced tumor penetration, and prolonged circulation time in the body. By optimizing drug pharmacokinetics and biodistribution, these formulations enhance treatment outcomes while minimizing off-target effects.

Ongoing research explores targeted endoscopic delivery systems for localized drug delivery and image-guided therapy in gastrointestinal NETs. Novel endoscopic platforms, such as drug-eluting stents, micro-injectors, and magnetic navigation systems, enable precise delivery of therapeutic agents directly to the tumor site. These targeted delivery systems enhance the efficacy and safety of treatment modalities, such as chemotherapy, immunotherapy, and peptide receptor radionuclide therapy (PRRT), by minimizing systemic exposure and off-target effects. Real-time imaging and navigation capabilities allow for precise localization and monitoring of therapeutic response, optimizing treatment outcomes while minimizing procedural complications.

Scope of the Report:
• The report analyses the Neuroendocrine Tumors (NETs) Market by Value (USD Million).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Pipeline Scenario.
• The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Epidemiology.
• The report presents the analysis of Neuroendocrine Tumors (NETs) Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Neuroendocrine Tumors (NETs) Market by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Route of Administration (Oral, Parenteral).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others).
• The report analyses the Neuroendocrine Tumors (NETs) Market by End User (Hospitals, Specialty Clinics, Radiation Centers).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by source, by application, by indication, & by end user.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Pfizer, Amgen, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Ipsen, Lantheus Holdings, and Boehringer Ingelheim.

Table of Content

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Strategic Recommendations
2.1 Establishment of specialist therapeutic centers
2.2 Organize campaigns to raise awareness

3. Global Neuroendocrine Tumors (NETs) Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Global Neuroendocrine Tumors (NETs) Market
3.2 Pipeline Scenario
3.3 Epidemiology: Global NETs Prevalence
3.4 Epidemiology: Global NETs Incidence
3.5 Global Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
3.6 Degree of Impact of Covid-19 on Neuroendocrine Tumors (NETs) Market
3.7 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
3.7.1 Global Neuroendocrine Tumors (NETs) Market, By Therapy Overview
3.7.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Therapy Overview
3.7.3 Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
3.7.4 Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
3.7.5 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
3.8 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
3.8.1 Global Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
3.8.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Route of Administration Overview
3.8.3 Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
3.8.4 Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
3.9 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
3.9.1 Global Neuroendocrine Tumors (NETs) Market, By Indication Overview
3.9.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Indication Overview
3.9.3 Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
3.9.4 Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
3.9.5 Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
3.9.6 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
3.10 Global Neuroendocrine Tumors (NETs) Market Segmentation: By End User
3.10.1 Global Neuroendocrine Tumors (NETs) Market, By End User Overview
3.10.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By End User Overview
3.10.3 Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
3.10.4 Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics By Value, 2020H-2030F (USD Million & CAGR)
3.10.5 Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Neuroendocrine Tumors (NETs) Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot

5. Americas Neuroendocrine Tumors (NETs) Market: Historic and Forecast

5.1 Americas Neuroendocrine Tumors (NETs) Market: Snapshot
5.2 Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.3 Americas Neuroendocrine Tumors (NETs) Market: Key Factors
5.4 Americas Neuroendocrine Tumors (NETs) Market: Segment Analysis
5.5 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
5.5.1 Americas Neuroendocrine Tumors (NETs) Market, By Therapy Overview
5.5.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
5.5.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
5.5.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
5.6.1 Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
5.6.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
5.6.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
5.7.1 Americas Neuroendocrine Tumors (NETs) Market, By Indication Overview
5.7.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
5.7.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
5.7.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
5.7.5 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
5.8 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By End User
5.8.1 Americas Neuroendocrine Tumors (NETs) Market, By End User Overview
5.8.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
5.8.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
5.8.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
5.9 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Country
5.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
5.9.2 United States Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.9.2.1 United States Neuroendocrine Tumors (NETs) Market, By Therapy
5.9.2.2 United States Neuroendocrine Tumors (NETs) Market, By Route of Administration
5.9.2.3 United States Neuroendocrine Tumors (NETs) Market, By Indication
5.9.2.4 United States Neuroendocrine Tumors (NETs) Market, By End User
5.9.3 Canada Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.9.3.1 Canada Neuroendocrine Tumors (NETs) Market, By Therapy
5.9.3.2 Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration
5.9.3.3 Canada Neuroendocrine Tumors (NETs) Market, By Indication
5.9.3.4 Canada Neuroendocrine Tumors (NETs) Market, By End User
5.9.4 Rest of Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.9.4.1 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy
5.9.4.2 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration
5.9.4.3 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication
5.9.4.4 Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User

6. Europe Neuroendocrine Tumors (NETs) Market: Historic and Forecast

6.1 Europe Neuroendocrine Tumors (NETs) Market: Snapshot
6.2 Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.3 Europe Neuroendocrine Tumors (NETs) Market: Key Factors
6.4 Europe Neuroendocrine Tumors (NETs) Market: Segment Analysis
6.5 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
6.5.1 Europe Neuroendocrine Tumors (NETs) Market, By Therapy Overview
6.5.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
6.5.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
6.5.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
6.6.1 Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
6.6.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
6.6.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
6.7.1 Europe Neuroendocrine Tumors (NETs) Market, By Indication Overview
6.7.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
6.7.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
6.7.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
6.7.5 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
6.8 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By End User
6.8.1 Europe Neuroendocrine Tumors (NETs) Market, By End User Overview
6.8.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
6.8.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
6.8.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
6.9 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Country
6.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
6.9.2 United Kingdom Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.9.2.1 United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy
6.9.2.2 United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration
6.9.2.3 United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication
6.9.2.4 United Kingdom Neuroendocrine Tumors (NETs) Market, By End User
6.9.3 Germany Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.9.3.1 Germany Neuroendocrine Tumors (NETs) Market, By Therapy
6.9.3.2 Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration
6.9.3.3 Germany Neuroendocrine Tumors (NETs) Market, By Indication
6.9.3.4 Germany Neuroendocrine Tumors (NETs) Market, By End User
6.9.4 France Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.9.4.1 France Neuroendocrine Tumors (NETs) Market, By Therapy
6.9.4.2 France Neuroendocrine Tumors (NETs) Market, By Route of Administration
6.9.4.3 France Neuroendocrine Tumors (NETs) Market, By Indication
6.9.4.4 France Neuroendocrine Tumors (NETs) Market, By End User
6.9.5 Spain Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.9.5.1 Spain Neuroendocrine Tumors (NETs) Market, By Therapy
6.9.5.2 Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration
6.9.5.3 Spain Neuroendocrine Tumors (NETs) Market, By Indication
6.9.5.4 Spain Neuroendocrine Tumors (NETs) Market, By End User
6.9.6 Rest of Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.9.6.1 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy
6.9.6.2 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration
6.9.6.3 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication
6.9.6.4 Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User

7. Asia Pacific Neuroendocrine Tumors (NETs) Market: Historic and Forecast

7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market: Snapshot
7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market: Key Factors
7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market: Segment Analysis
7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
7.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy Overview
7.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
7.5.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
7.5.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
7.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
7.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
7.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
7.7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication Overview
7.7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
7.7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
7.7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
7.7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
7.8 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By End User
7.8.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User Overview
7.8.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
7.8.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
7.8.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
7.9 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Country
7.9.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Country Overview
7.9.2 China Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.9.2.1 China Neuroendocrine Tumors (NETs) Market, By Therapy
7.9.2.2 China Neuroendocrine Tumors (NETs) Market, By Route of Administration
7.9.2.3 China Neuroendocrine Tumors (NETs) Market, By Indication
7.9.2.4 China Neuroendocrine Tumors (NETs) Market, By End User
7.9.3 Japan Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.9.3.1 Japan Neuroendocrine Tumors (NETs) Market, By Therapy
7.9.3.2 Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration
7.9.3.3 Japan Neuroendocrine Tumors (NETs) Market, By Indication
7.9.3.4 Japan Neuroendocrine Tumors (NETs) Market, By End User
7.9.4 India Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.9.4.1 India Neuroendocrine Tumors (NETs) Market, By Therapy
7.9.4.2 India Neuroendocrine Tumors (NETs) Market, By Route of Administration
7.9.4.3 India Neuroendocrine Tumors (NETs) Market, By Indication
7.9.4.4 India Neuroendocrine Tumors (NETs) Market, By End User
7.9.5 South Korea Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.9.5.1 South Korea Neuroendocrine Tumors (NETs) Market, By Therapy
7.9.5.2 South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration
7.9.5.3 South Korea Neuroendocrine Tumors (NETs) Market, By Indication
7.9.5.4 South Korea Neuroendocrine Tumors (NETs) Market, By End User
7.9.6 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.9.6.1 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy
7.9.6.2 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration
7.9.6.3 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication
7.9.6.4 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User

8. Middle East and Africa Neuroendocrine Tumors (NETs) Market: Historic and Forecast

8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Snapshot
8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Key Factors
8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Segment Analysis
8.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
8.5.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Therapy Overview
8.5.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
8.5.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
8.5.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
8.6.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
8.6.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
8.6.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
8.7 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
8.7.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Indication Overview
8.7.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
8.7.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
8.7.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
8.7.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
8.8 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By End User
8.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By End User Overview
8.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
8.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
8.8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global Neuroendocrine Tumors (NETs) Market
9.2 Drivers
9.3 Restraints
9.4 Trends

10. Industry Ecosystem Analysis
10.1 Porter Analysis

11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Share of Leading Companies
11.3 Company Profiling
11.3.1 Novartis
11.3.2 Pfizer
11.3.3 Amgen, Inc.
11.3.4 GlaxoSmithKline
11.3.5 F. Hoffmann-La Roche AG
11.3.6 Bristol-Myers Squibb Co.
11.3.7 Eli Lilly and Company
11.3.8 Ipsen
11.3.9 Lantheus Holdings
11.3.10 Boehringer Ingelheim

12. About Us and Disclaimer

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.

Related Reports

Global Management Of Malignant Tumors Market Size, Key Players, Research Insights, Emerging Opp...
View More
2023-2028 Global And Regional Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry...
View More
Global Basketball Nets And Hoops Market Size, Key Players, Research Insights, Emerging Opportun...
View More
2023-2028 Global And Regional Neuroendocrine Function Test Industry Status And Prospects Profes...
View More
2023-2028 Global And Regional Packaging Nets Industry Status And Prospects Professional Market ...
View More

Trusted Clients
A-T- Kearney.png
AbbVie.png
Agrinos.png
AIF-Metrics.png
Akzo-Nobel.jpg
Alfi-GMBH.png
Allergan.png
Almasra-Scientific-Bureau.jpg
ALPMA.jpg
Americana-Foods.png
ANP.png
Aptar-Group-Germany.jpg
asahi-kasei.png
ATC.png
atlas-servair.jpg
ATOS.png
Avalon.png
biofishency.png
biomx.png
borealisgroup.png
Cape-Peninsula.png
CBRE.png
Cennerv-Pharma.jpg
Clearponds.png
Compass-Group.png
Cortag-Industria.png
Covis-Pharma.jpg
DAIMLER-AG.jpg
Edipresse-Media.jpg
Epson.png
Evonik-Industries-AG.png
ExcelSource.png
Fingo.png
Firstkind.png
FLM-Foodingredients.png
Freudenberg.png
Fueltrax.jpg
Fugro-International.png
Fuji-Films.png
Funky-Sound-Studio.png
GALTWAY.png
Gartner.png
GBSC.png
Global-Information.jpg
Hanwha-Total-Petrochemical.png
Hebrew.png
Horiba-Mira.png
Hunter-and-Co-Investments.png
Hyosung.png
Hyssopus-Organics.jpg
IBSA.png
Ideagen.png
IMS.png
InSinkErator.png
Intas-Pharma.png
IntelMed-Sarl.png
Interdiligence-Consulting.png
Israel-Shopyards.png
Johnsons-Controls.png
kakaxi.jpg
KORDSA.png
kotra.png
KPMG.png
lantmannen.png
LEK.png
LG.jpg
Makuri-Technology.jpg
Mallinckrodt.png
Mappo.png
Maprimed.jpg
mcns.jpg
MED-EL.png
Mehr-Azin-Pouya-Sahand.png
Molkerei-Ammerland-eG.png
Monty-Holding.jpg
mpmaterials.png
Mundipharma.png
Nasco.png
Nitto.png
Nouryon.png
NOXTAK.png
Oskars.png
Paidotribo.png
Parnell-Pharmaceuticals.png
Podravka.png
ppg.png
Privi.png
Publicis Groupe.png
Qvetech.jpg
R3P.jpg
Samsung.png
Sapient.png
SEW-EURODRIVE.png
Shivananda.jpg
Silver-Clouds.png
SMIT.jpg
SOLVIAS.png
Spectrum.png
SR-Instruments-Oy.png
Star-Seed.png
Stryker -ENT.png
Synjenta.png
Terumo-Corp.png
TherOzone.png
Toshiba.png
TT-Electronics.png
umbc.edu.png
Vard.jpg
Vital-Xense.png
Walraven.png
Wlgore.png
Woodmac.png
WWF-UK.png
ZENOAQ.png
Zuellig-Pharma.png
Contact us

sales@worldwidemarketreports.com

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

phoneiconU.S. : +1 415 871 0703

phoneiconU.K. : +44-203-289-4040

phoneiconAUS. :+61-2-4786-0457

phoneiconIndia :+91-848-285-0837

Menu
Quick Links
Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved